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Abstract 1 
Rationale: Chronic elevation of 3’-5’-cyclic adenosine monophosphate (cAMP) levels has been 2 
associated with cardiac remodelling and cardiac hypertrophy. However, enhancement of particular 3 
aspects of cAMP/protein kinase A (PKA) signalling appears to be beneficial for the failing heart. 4 
cAMP is a pleiotropic second messenger with the ability to generate multiple functional outcomes 5 
in response to different extracellular stimuli with strict fidelity, a feature that relies on the spatial 6 
segregation of the cAMP pathway components in signalling microdomains.   7 
Objective: How individual cAMP microdomains impact on cardiac pathophysiology remains largely 8 
to be established. The cAMP-degrading enzymes phosphodiesterases (PDEs) play a key role in 9 
shaping local changes in cAMP. Here we investigated the effect of specific inhibition of selected 10 
PDEs on cardiac myocyte hypertrophic growth. 11 
Methods and results:  Using pharmacological and genetic manipulation of PDE activity we found 12 
that the rise in cAMP resulting from inhibition of PDE3 and PDE4 induces hypertrophy whereas 13 
increasing cAMP levels via PDE2 inhibition is anti-hypertrophic. By real-time imaging of cAMP 14 
levels in intact myocytes and selective displacement of PKA isoforms we demonstrate that the anti-15 
hypertrophic effect of PDE2 inhibition involves the generation of a local pool of cAMP and 16 
activation of a PKA type II subset leading to phosphorylation of the nuclear factor of activated T 17 
cells (NFAT). 18 
Conclusions: Different cAMP pools have opposing effects on cardiac myocyte cell size. PDE2 19 
emerges as a novel key regulator of cardiac hypertrophy both in vitro and in vivo and its inhibition 20 
may have therapeutic applications.  21 
 22 
Key words: Hypertrophy, signal transduction, cAMP, protein kinase A, phosphodiesterases 2 23 
 24 
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Non-standard Abbreviations and Acronyms  1 
AC: adenylyl cyclase 2 
AKAP: A kinase anchoring protein 3 
ANP: atrial natriuretic peptide 4 
ARVM: adult rat ventricular myocyte 5 
cAMP: 32-52-cyclic adenosine monophosphate 6 
CaN: Ca2+-calmodulin dependent phosphatase 7 
D/D: dimerization/docking domain 8 
EHNA: (erythro-9-(2-hydroxy-3-nonyl)adenine) 9 
Epac: Exchange factor activated by cAMP 10 
FRET: fluorescence resonance energy transfer 11 
ISO: isoproterenol 12 
NE: norepinephrine 13 
NFAT: nuclear factor of activated T cells 14 
NRVM: neonatal rat ventricular myocyte 15 
PDE: phosphodiesterase 16 
PKA: protein kinase A 17 
PKG: protein kinase G 18 
TAC: transverse aorta constriction 19 
  20 
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Introduction 1 
The pleiotropic second messenger 32-52-cyclic adenosine monophosphate (cAMP) mediates the 2 
catecholaminergic control on heart rate and contractility and, at the same time, is responsible for 3 
the functional response of the heart to a wide variety of other hormones and neurotransmitters. 4 
cAMP signalling is also central to the pathogenesis of a number of conditions including cardiac 5 
hypertrophy, arrhythmia and heart failure1. An important advance in cardiac adrenergic signal 6 
transduction is the realisation in the past decade that the high fidelity with which cAMP mediates a 7 
plethora of different functions relies on the spatial segregation of the molecular components of this 8 
signalling pathway within subcellular microdomains2, 3. The hormonal specificity of cAMP action 4 9 
results from the generation of distinct pools of the second messenger which in turn mediate 10 
different functional outcomes via activation of different subsets of the cAMP effector protein kinase 11 
A (PKA)5, 6.  PKA is a holotetrameric enzyme composed of a dimer of regulatory (R) and two 12 
catalytic (C) subunits. In the heart two PKA isoforms are expressed, PKA type I and PKA type II, 13 
which differ in their R subunit. In cardiac myocytes PKA is largely localized to different subcellular 14 
compartments6 via binding to a family of scaffolding proteins known as A Kinase Anchoring 15 
Proteins (AKAPs)7. Apart from their common ability to anchor PKA, AKAPs show a high degree of 16 
structural variability which allows for different subcellular localisation and binding to a variety of 17 
signalling components. As a result, AKAPs serve as signalling centres, where specific binding 18 
partners are organised for a particular task. Localisation of PKA is achieved through the interaction 19 
of the amino-terminal dimerization/docking (DD) domain of the R subunits8 with the AKAP, and 20 
serves to anchor PKA in proximity to selected targets thus favouring their preferential 21 
phosphorylation9-11. The AKAP-D/D interaction is also responsible for differential targeting of the 22 
two PKA isoforms, with different AKAPs showing different specificity of binding for RI and RII 12 as 23 
a consequence of differences within the docking interface in R13.  24 
The intracellular concentration of cAMP is tightly regulated by the cyclic nucleotide degrading 25 
enzymes PDEs. PDEs are a large superfamily of enzymes including 11 families (PDE1-11) with a 26 
number of different genes and splice variants generating close to 100 isozymes showing unique 27 
kinetic, regulatory and subcellular localization properties14. PDEs play a pivotal role in shaping 28 
local cAMP signals by limiting cAMP diffusion beyond a microdomain and by regulating cAMP 29 
levels within a microdomain.  As a consequence, inhibition of individual PDE families results in a 30 
compartmentalised increase in cAMP as shown by studies using targeted reporters and real time 31 
imaging of cAMP levels in intact myocytes 15, 16. 32 
We have previously reported that in intact neonatal rat ventricular myocytes (NRVMs) PDE2, PDE3 33 
and PDE4 are localised at distinct subcellular sites and uniquely modulate the cAMP response to 34 
individual extracellular stimuli17,18. In NRVM cell lysates PDE3 and PDE4 account for most of the 35 
PDE activity whereas PDE2 is responsible for only a minor fraction of cAMP hydrolytic activity17. 36 
However, in intact NRVMs, in spite of its low abundance, PDE2 plays a major role in the control of 37 
the cAMP response to catecholamines18, an effect that relies on its specific localisation within the 38 
cell16.   39 
 40 
Although the concept of compartmentalised cAMP/PKA signalling in cardiac myocytes is well 41 
established and the physiological function downstream of individual cAMP pools is being 42 
elucidated10, 11, 19, 20, very little is known about the role of local cAMP pools in the pathogenesis of 43 
heart disease. Catecholamines induce cardiac hypertrophy via mechanisms that include activation 44 
of ² -adrenergic receptors, generation of cAMP and PKA-mediated elevation of intracellular Ca2+ 21. 45 
Although chronic stimulation of ² -adrenergic signalling leads to pathologic sequelae, enhancement 46 
of particular aspects of cAMP/PKA signalling benefits the failing heart22-24, suggesting that different 47 
components of this pathway may have different consequences on cardiac hypertrophy and failure.  48 
 49 
In this study we investigate the effect on cardiac hypertrophy of local manipulation of cAMP levels 50 
via selective inhibition of individual PDEs. We find that distinct pools of cAMP differently affect 51 
cardiac myocyte hypertrophic growth and that inhibition of PDE2, unlike inhibition of PDE3 or 52 
PDE4, results in anti-hypertrophic effects both in vitro and in vivo.  We further demonstrate that 53 
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increased PDE2 activity is sufficient per se to induce hypertrophy. The anti-hypertrophic effect of 1 
PDE2 inhibition relies on a local increase in cAMP that enhances PKA-mediated phosphorylation 2 
of NFAT and its consequent retention in the cytosol. We conclude that PDE2 regulates a pool of 3 
cAMP with unique effects on cardiac myocyte hypertrophic growth and identify PDE2 as a potential 4 
novel therapeutic target.   5 
 6 
Materials and Methods 7 
A detailed description of the Materials and Methods is included in the online data supplement to 8 
this article. 9 
 10 
Results 11 
PDE2 inhibition counteracts cardiac myocyte hypertrophy both in vitro and in vivo. 12 
Treatment of NRVMs with 10 µmol/L norepinephrine (NE) for 48 hours is a well-established in vitro 13 
model of cardiac hypertrophy25 eliciting the expected hypertrophy markers, including increase in 14 
cell surface area, 3H-leucine incorporation, nuclear translocation of NFAT (Fig. 1B-D) and ANP 15 
levels (Suppl. Fig. 1A). To investigate the effect of raising cAMP levels on cardiac myocyte 16 
hypertrophy, we treated NRVMs with different cAMP-raising agents (Fig. 1A). Activation of 17 
adenylyl cyclase with 1 µmol/L forskolin, inhibition of PDE4 with 10 µmol/L rolipram and inhibition 18 
of PDE3 with 10 µmol/L cilostamide generated significant hypertrophy (Fig. 1B-D). In contrast, 19 
inhibition of PDE2 with BAY 60-7550 (10 µmol/L) did not induce hypertrophy (Fig. 1B-D), despite 20 
generating an increase in cAMP as the other treatments (Fig. 1A). The unique effect of PDE2 21 
inhibition was also apparent in cells co-treated with NE. When cilostamide and rolipram were 22 
administered in combination with 10 µmol/L NE, NE further increased cell size compared to 23 
inhibitor alone, although no further enhancement of hypertrophy was observed compared to NE 24 
alone (compare Fig. 1B-D and 1F-I). In contrast, BAY 60-7550 blocked the hypertrophic growth 25 
induced by NE (Fig. 1 F-I and Suppl Fig 1A-F), despite its potentiation of the NE-induced cAMP 26 
response (Fig. 1E). The anti-hypertrophic effect of BAY 60-7550 was confirmed at 50 nmol/L of 27 
inhibitor (Suppl. Fig. 1B).  Similar results were found with EHNA (erythro-9-(2-hydroxy-3-28 
nonyl)adenine), another selective PDE2 inhibitor (Suppl. Fig. 1C), in cardiomyocytes from 29 
neonatal mice (Suppl. Fig. 1D) and in adult rat ventricular myocytes (ARVMs) (Suppl. Fig. 1E-F). 30 
Similar effects on cell size (Fig. 1J) and NFAT-GFP nuclear translocation (Fig. 1K) were found 31 
when PDE2 expression was knocked down using the small interfering RNA sequence siPDE216. 32 
The specificity of the siRNA effect was confirmed by rescue experiments (Suppl. Fig. 2). BAY 60-33 
7550 also blocked the hypertrophy induced by treatment with 10 µmol/L isoproterenol (Fig. 1G) 34 
whereas it had no effect on the hypertrophy induced by phenylephrine (PE, Fig. 1L), indicating that 35 
PDE2 acts downstream of the ² - rather than the ±-adrenergic receptor. Consistently, Bay 60-7550 36 
did not inhibit PE-induced NFAT nuclear translocation (Suppl. Fig. 1G) and did not affect the 37 
nuclear translocation of NFAT in response to PE and selective inhibition of GSK3²  and JNK 38 
(Suppl. Fig. 1G), indicating that inhibition of PDE2 acts independently of this pathway.  39 
To examine whether PDE2 inhibition also attenuates cardiac hypertrophy in vivo, adult C57Bl/6 40 
mice were subjected to transverse aorta constriction (TAC) for 3 weeks and concurrently treated 41 
with BAY 60-7550 (3mg/kg) or with vehicle (Suppl. Table 1). The PDE2 inhibitor induced a 42 
significant reduction of cardiac hypertrophy as verified by echocardiography (Suppl. Fig. 1H-I), 43 
cardiac MRI (Fig. 2 A-B) and post-mortem examination (Fig. 2C-H). 44 
 45 
PDE2 overexpression results in cardiac myocyte hypertrophy both in vitro and in vivo. We 46 
next investigated the effect of increasing PDE2 activity in NRVMs by overexpressing a Red 47 
Fluorescent Protein-tagged version of PDE2 (PDE2Awt-mRFP). We found a significant increase in 48 
cell surface area (Fig. 3A-B) and in nuclear translocation of NFAT-GFP (Fig. 3C) in transfected 49 
versus untransfected cells. Overexpression of a catalytically inactive version of the enzyme 50 
(dnPDE2Awt-mRFP) had no effect (Fig 3D and 5E).  Similar results were found in ARVMs (Suppl. 51 
Fig. 3A-D).To test whether overexpression of PDE2 results in hypertrophic growth in vivo, a 52 
recombinant adenoviral vector (Ad) expressing the PDE2A enzyme tagged with mCherry 53 
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(AdV5/PDE2Awt-mCherry) was injected in the heart of adult rats. Seven days after injection, the 1 
cell surface areas of transduced and untransduced myocytes dissociated from the same heart 2 
were compared. As shown in Fig. 3E-F, PDE2Awt-mCherry expressing cardiomyocytes show a 3 
significant increase in cell surface area as compared to untransduced cells; cardiomyocytes 4 
overexpressing the catalytically inactive PDE2Adn-mCherry did not differ from untransduced cells 5 
(Fig. 3E, G).  6 
 7 
 8 
The anti-hypertrophic effect of PDE2 inhibition is PKA-dependent. PDE2 can degrade both 9 
cAMP and cGMP26 therefore its inhibition may result in an increase of both second messengers. 10 
To establish whether PKA or PKG mediates the anti-hypertrophic effect of PDE2 inhibition we 11 
measured cell surface area and NFAT-GFP nuclear translocation in NE-treated NRVMs in the 12 
presence of selective kinase inhibitors. The selective PKG inhibitor DT-227 did not affect the ability 13 
of BAY 60-7550 to significantly reduce hypertrophy (Fig. 4A, B). As a control we measured the 14 
effect of DT-2 on the anti-hypertrophic effect of selective inhibition of the cGMP-specific PDE5 with 15 
sildenafil (10 nmol/L), previously reported to counteract hypertrophy via PKG activity28. We found 16 
that sildenafil alone had no effect on either cells surface area or NFAT-GFP nuclear translocation  17 
(Suppl. Fig. 4) but DT-2 completely blocked the cGMP-mediated effect of sildenafil on NE-induced 18 
cell size increase (Fig. 4A) and NFAT-GFP nuclear translocation (Fig. 4B). In contrast, selective 19 
PKA inhibition with myrPKI29 completely abolished the anti-hypertrophic effects of BAY 60-7550 20 
(Fig. 4C,D) without affecting the anti-hypertrophic effect of sildenafil (Fig. 4C-D). In keeping with 21 
these findings, the effect of PDE2 knock-down on NE-induced hypertrophy was completely blocked 22 
by myrPKI but was unaffected by DT-2 treatment (Fig. 4E-F). Consistent with a role for PKA 23 
activation downstream of PDE2 inhibition, we found that Bay 60-7550 significantly increases PKA-24 
mediated phosphorylation of the FRET reporter AKAR4 (Suppl. Fig. 5). The role of PKA is further 25 
supported by the finding that the anti-hypertrophic effect of BAY 60-7550 is completely blocked by 26 
the PKA inhibitors H89 and cAMPS-Rp  (Fig. 4G). In addition, we found that disrupting PKA-27 
AKAPs interactions with the competing peptide Ht3130 abolishes the effect of BAY 60-7550 on 28 
nuclear translocation of NFAT, (Fig. 4H), confirming a PKA-dependent mechanism and indicating 29 
that a localised subset of PKA is involved. Thus, the anti-hypertrophic effect of PDE2 is PKA-30 
mediated and PKG-independent. 31 
 32 
 33 
PDE2 modulates a local pool of cAMP with anti-hypertrophic effects. PDE2 has been shown 34 
to be targeted to specific subcellular sites in NRVMs18, a finding that we confirm here in ARVMs 35 
(Suppl. Fig.6). A possible explanation for the opposite effect on cell size observed on selective 36 
PDE inhibition is that blocking the activity of a localised PDE2 raises cAMP content in a specific 37 
subcellular microdomain that is linked to anti-hypertrophic effects, whereas inhibition of PDE3 and 38 
PDE4 increases cAMP at sites where pro-hypertrophic effectors are activated. If so, it should be 39 
possible to recapitulate the effect of selective pharmacological inhibition by displacing the 40 
individual PDEs from their anchor sites within the cell, a manoeuvre that has been previously used 41 
to generate a localised increase in cAMP16, 31. To test this, we measured cell surface area in 42 
NRVMs overexpressing fluorescent protein-tagged chimeras of catalytically inactive mutants of 43 
PDE2A (PDE2Adn)16, PDE3A2 (PDE3A2dn) and PDE4D3 (PDE4D3dn)32. We found that 44 
displacement of endogenous PDE4D3 (Fig. 5A) or PDE3A2 (Fig. 5C) resulted in hypertrophy, and 45 
did not further increase the hypertrophy induced by NE treatment (Fig. 5B, D), reproducing the 46 
effects of pharmacological inhibition. In contrast, displacement of endogenous PDE2A did not 47 
affect cell size in untreated myocytes (Fig. 5E) but significantly reduced the hypertrophy induced 48 
by NE (Fig. 5F). Similar results were found for nuclear translocation of NFAT-GFP (Suppl. Fig. 49 
7A, B) and in ARVMs (Suppl. Fig. 7C-F). These data support a model whereby different PDEs 50 
localised to different intracellular locations control distinct pools of cAMP with opposite effects on 51 
cardiac myocyte cell size.  52 
 53 
The anti-hypertrophic effect of PDE2 inhibition is mediated by PKAII. The data presented so 54 
far demonstrate that a local pool of cAMP with anti-hypertrophic effects is selectively regulated by 55 
PDE2-mediated hydrolysis. To gain some insight into the subcellular localisation of such a pool we 56 
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measured the cAMP signal generated on selective PDE2 inhibition using RI_epac and RII_epac, 1 
two FRET-based reporters for cAMP that localise to the sites where PKAI and PKAII, respectively, 2 
normally reside within the cell. These reporters target to different AKAPs and have been previously 3 
shown to selectively detect cAMP signals within distinct subcellular compartments6. PDE2 4 
inhibition potentiates the cAMP response to 10 nmol/l NE (Fig. 6A) or 10 nmol/L ISO (Suppl. Fig. 5 
8A) both in the PKAI and PKAII compartments, whereas PDE3 inhibition affects the cAMP 6 
response exclusively in the PKAI compartment (Fig. 6B and Suppl. Fig. 8B). Similar results were 7 
found in ARVM (Suppl. Fig 8D-E).  As inhibition of PDE3 promotes, rather than inhibit, 8 
hypertrophy (Fig 1A, D) we hypothesised that the cAMP pool under the control of PDE2 and 9 
responsible for the anti-hypertrophic effect is associated with the PKAII compartment. Consistent 10 
with this model we found that, on inhibition of PDE2, PKA-mediated phosphorylation is significantly 11 
higher in the PKAII compartment as opposed to the PKAI compartment (Fig 6D). In addition, the 12 
effect of PDE2 inhibition on hypertrophy was completely blocked by SuperAKAP-IS12, a peptide 13 
that disrupts selectively the interaction between PKAII and AKAPs, whereas the PKAI-AKAP 14 
selective disruptor RIAD33  had no affect  (Fig 6E-F), confirming that a subset of AKAP-anchored 15 
PKAII mediates the antihypertrophic effect downstream of PDE2 inhibition. Interestingly, the pro-16 
hypertrophic effect of PDE3 and PDE4 inhibition, although PKA-dependent (Fig 6G) was not 17 
affected by treatment with either SuperAKAP-IS or RIAD (Fig 6H-I), suggesting that the 18 
prohypertrophic effect of PDE3 and PDE4 inhibition does not require an AKAP-anchored subset of 19 
PKA.  20 
 21 
The anti-hypertrophic effect of PDE2 inhibition requires PKA-mediated phosphorylation of 22 
NFAT. Nuclear translocation of NFAT regulates pathological cardiac hypertrophy34. PKA 23 
phosphorylates NFAT at Ser 245, Ser 269 and Ser 29435, thus preventing its nuclear 24 
translocation36. We therefore hypothesised that the anti-hypertrophic effects of PDE2 inhibition 25 
may rely on PKA-mediated phosphorylation of NFAT. Consistent with our hypothesis treatment of 26 
NRVM with Bay 60-7550 results in strong enhancement of PKA-dependent phosphorylation of 27 
NFAT (Fig 7A). In addition, in a pull-down of PKA-phosphorylated proteins from lysates of NRVMs 28 
hypertrophied in vitro the amount of PKA-phosphorylated NFAT-GFP was significantly higher in 29 
BAY 60-7550 treated than in control cells (Fig. 7B and Suppl. Fig. 9C-D). Similar results were 30 
obtained from NFAT-GFP pull downs probed with a PKA substrate antibody (Suppl Fig. 9A-B). 31 
Notably, increased phosphorylation on inhibition of PDE2 was confirmed when probing for 32 
endogenous NFAT (Fig. 7 C). It is interesting to note that PDE4 inhibition increase PKA-mediated 33 
phosphorylation of overexpressed NFAT-GFP (Fig. 7B and Suppl. Fig. 9C-D), in line with the 34 
large global rise in cAMP that it generates (Fig. 1C). Overexpressed NFAT is likely to distribute to 35 
sites where endogenous NFAT normally is not present and therefore it is expected to become 36 
phosphorylated on PDE4 inhibition. However, PDE4 inhibition does not significantly affect the 37 
phosphorylation of endogenous NFAT (Fig. 7C), further confirming that PDE2 and PDE4 act on 38 
distinct pools of cAMP and have distinct effects on the endogenous protein. To further test whether 39 
the anti-hypertrophic effect of BAY 65-7550 is mediated by PKA-dependent phosphorylation of 40 
NFAT, we generated a PKA phosphorylation-resistant form of NFAT-GFP by introducing serine-to-41 
alanine substitutions at positions 245, 269 and 294. BAY 60-7550 reduced the translocation of wild 42 
type NFAT-GFP but did not affect nuclear translocation of triple-mutant NFAT-GFP (Fig. 7D), 43 
indicating that the PKA-phosphorylation sites on NFAT are required for BAY 60-7550 to prevent 44 
NE-induced nuclear translocation of NFAT. In contrast, treatment of hypertrophic myocytes with 45 
sildenafil significantly blocked nuclear translocation of both wild type and triple mutant NFAT-GFP 46 
(Fig. 7D), as expected given that the anti-hypertrophic effect mediated by sildenafil is independent 47 
of PKA phosphorylation (Fig. 2 and 27). Inhibition of PDE4 with rolipram did not affect the nuclear 48 
translocation of either wt or triple-mutant NFAT (Fig. 7D). In further support of the role of a local 49 
pool of cAMP in the anti-hypertrophic effect of PDE2 inhibition, overexpression of PDE2Adn-mRFP 50 
in NE-treated NRVMs reduced nuclear translocation of NFAT-GFP (Suppl. Fig. 10A) but not of 51 
triple mutant NFAT-GFP (Suppl. Fig. 10B). In addition, in the presence of triple mutant NFAT-52 
GFP, PDE2Adn-mRFP was unable to counteract NE-induced hypertrophy (Suppl. Fig. 10C-D), 53 
further confirming that the anti-hypertrophic effect of PDE2 requires PKA-mediated phosphorylation 54 
of NFAT. The involvement of NFAT phosphorylation and NFAT-dependent gene transcription in the 55 
anti-hypertrophic effect of PDE2 inhibition in vivo was confirmed in experiments where we 56 
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measured NFAT phosphorylation (Fig. 7E) and mRNA levels for BNP and RCAN1 (Fig. 7F), two 1 
genes that are transcribed under the control of NFAT 34, 37 in sham operated, TAC+vehicle and 2 
TAC+BAY 60-7550 treated mice. We found that treatment with the PDE2 inhibitor significantly 3 
enhances NFAT phosphorylation and reduces the level of expression of NFAT-dependent genes, 4 
thus reversing the molecular fingerprint of pathological hypertrophy. To further support our 5 
conclusion that PDE2 inhibition counteracts cardiac hypertrophy in vivo via an NFAT-dependent 6 
mechanism we subjected NFAT reporter mice38 to TAC and randomization to treatment with BAY 7 
60-7550 or vehicle for two weeks (Suppl. Table 2 and Suppl. Figure 11). In line with our previous 8 
results BAY 60-7550 treated NFAT reporter mice showed reduced cardiac hypertrophy (Suppl. Fig 9 
11) and corresponding NFAT luciferase activity (Fig. 7G) after TAC as compared to vehicle treated 10 
mice. 11 
 12 
Discussion 13 
In this study we identify PDE2 as a regulator of cardiac hypertrophy by providing strong evidence, 14 
both in vitro and in vivo, that overexpression of PDE2 is sufficient per se to induce hypertrophy and 15 
that inhibition of PDE2 counteracts cardiac myocyte hypertrophic growth, an effect that relies on 16 
cAMP-dependent activation of PKA.  Our data reveal a completely novel mechanism through which 17 
cAMP signalling impacts cardiac myocyte cell size that strictly depends on the subcellular site at 18 
which the cAMP signal is generated. Thus, inhibition of PDE2 generates a local pool of cAMP with 19 
anti-hypertrophic effects, whereas the rise in cAMP generated via inhibition of PDE3 or PDE4 has 20 
pro-hypertrophic effects. We demonstrate here for the first time that spatially distinct pools of cAMP 21 
can be generated downstream of ² AR activation with opposing effects on myocyte cell size. 22 
Using targeted FRET reporters for cAMP and selective displacement of PKAI and PKAII from their 23 
anchoring sites on AKAPs we unveil a complex involvement of cAMP and PKA in regulation of 24 
cardiac myocyte hypertrophic growth. Inhibition of PDE2 and PDE4 results in a cAMP increase in 25 
both the PKAI and PKAII compartments, yet the effect on cell size is opposite. To rationalise these 26 
findings, it should be noted that in cardiac myocytes there are multiple PKAI-AKAP and PKAII-27 
AKAP complexes7 and that the PKAI- and PKAII-targeted FRET reporters do not discriminate 28 
between individual complexes. Thus, although inhibition of both PDE2 and PDE4 generates a 29 
predominant rise in cAMP in the PKAII compartment, the rise in cAMP may affect different PKAII-30 
AKAP complexes. Our findings support a model whereby a pool of cAMP generated in the PKAII 31 
compartment on PDE2 inhibition counteracts hypertrophy whereas a pool of cAMP generated on 32 
inhibition of PDE4 within the PKAII compartment, but presumably involving different PKAII-AKAP 33 
complexes, has no effect on cell size. Alternatively, inhibition of PDE4 may affect the same pool of 34 
cAMP under the control of PDE2, but a concomitant increase in cAMP at a different site has a 35 
dominant, pro-hypertrophic effect. In support of the latter, using PKA-AKAP selective disruptors we 36 
find that inhibition of PDE4, as well as inhibition of PDE3, result in hypertrophy via activation of a 37 
subset of PKA that is not anchored to AKAPs.  38 
It is well established that adrenergic stimulation can initiate cardiac hypertrophy via generation of 39 
cAMP and activation of PKA39, 40, as confirmed by PKA knockout studies in which deletion of PKA 40 
subunits is protective against hypertrophy41. Other studies, however, have suggested that 41 
components of the ² -adrenergic signalling pathway may play a protective role in response to 42 
haemodynamic overload. For example, it has been reported that over-expression of some types of 43 
adenylyl cyclase improve cardiac function23 and that PKA-mediated phosphorylation of histone 44 
deacetylase 5 prevents its nuclear export and results in decreased cardiac myocyte size42. The 45 
present data support the coexistence within the same cell of multiple spatially segregated 46 
cAMP/PKA signalling pathways that can alternatively prevail depending on the status of the cell 47 
and provide a possible mechanistic basis for the dichotomy reported in the literature on the role of 48 
PKA on the development of cardiac pathology. 49 
 50 
Dephosphorylation of NFAT and its subsequent translocation to the nucleus is regulated by the 51 
Ca2+-calmodulin dependent phosphatase (CaN), one of the most potent activators of the 52 
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hypertrophic programme34. It is interesting to note that CaN can directly interact with a number of 1 
AKAPs, including AKAP143, AKAP544 and AKAP645, all of which bind PKA type II. In addition, 2 
studies suggest that regulation of CaN activity occurs via a specific microdomain of Ca2+ 46, further 3 
supporting a local regulation of this phosphatase. Although NFAT has not been reported to be part 4 
of a macromolecular complex organised by AKAPs, there is some evidence that this transcription 5 
factor also resides in distinct cytosolic domains and that its regulation occurs locally47. Based on 6 
the above observations, a possible scenario is therefore that PDE2 controls a pool of cAMP that 7 
activates an AKAP-bound PKA type II to phosphorylate a local NFAT, possibly counterbalancing its 8 
dephosphorylation by a local CaN. Further studies are required to explore this hypothesis. 9 
 10 
Recently it has been reported by Mehel et al. that NE treatment does not significantly increase cell 11 
size in ARVM overexpressing PDE248. Based on this observation the authors suggest that PDE2 12 
may be protective against pathological hypertrophy. Unfortunately that report show only normalised 13 
values of the effect of NE on cells overexpressing PDE2 and not  the effect on cell size of 14 
overexpression of PDE2 per se , making the data difficult to interpret. We note however that, 15 
although the authors draw to the opposite conclusion, the data as reported by Mehel et al. are 16 
compatible with the findings described in the present report. If we were to express the effect of NE 17 
on cell size relative to control cells and relative to PDE2 overexpressing cells, as reported in the 18 
Mehel et al study, the latter group would show a significantly blunted effect of NE treatment (see 19 
Suppl. Fig. 12 and refer to Suppl. Fig. 3A-B and Suppl. Fig. 7E-F). However, this way of 20 
presenting the data is misleading as overexpression of PDE2 already results in very significant 21 
hypertrophy compared to control cells (see Fig. 3 and Suppl. Fig. 3), thus reducing the relative 22 
effect of NE.  23 
 24 
Our findings may have important clinical implications. The in vivo data provide a first indication that 25 
inhibition of PDE2 counteracts hypertrophy in a TAC model. Additional investigations will be 26 
required to establish whether this would protect from progression toward heart failure and the 27 
relevance of PDE2 activity to human cardiac hypertrophy. Interestingly, increased levels of PDE2 28 
expression have been reported in early rat cardiac hypertrophy49 as well as in failing human 29 
hearts50, suggesting that increased activity of this enzyme may be involved in the pathogenesis of 30 
the disease. It has been suggested that the hypertrophic response to pathological stress is never 31 
truly 'adaptive'51 and that inhibition of hypertrophy is beneficial52-54. In addition the possibility to 32 
control the local concentration of cAMP at specific sites via selective inhibition of PDEs has been 33 
previously recognized as a possible approach to improving clinical outcomes55 and a phase 3 trial 34 
has been recently concluded where the PDE3 selective inhibitor enoximone was used in 35 
combination with ² -blockade to couple inhibition of adverse ² -adrenergic signalling with restoration 36 
of phospholamban phosphorylation56. In this perspective, PDE2 may represent a particularly 37 
interesting target. In vitro studies have demonstrated that the pool of cAMP generated upon 38 
inhibition of PDE2 mediates positive inotropic effects18, 57 and the ability to manipulate a pool of 39 
cAMP that simultaneously exerts positive inotropy and counteracts cardiac myocyte hypertrophic 40 
growth may represent a significant improvement over existing therapeutic strategies. 41 
 42 
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This study was supported by the Fondation Leducq (O6 CVD 02), the British Heart Foundation 44 
(PG/10/75/28537 and RG/12/3/29423) to MZ. 45 
 46 
Disclosures: None 47 
  48 
CIRCRES/2014/305892D/R1 10 
 
10 
 
 1 
Figure 1. Effect of PDE2 inhibition on cardiac myocyte hypertrophy in vitro 2 
(A) cAMP increase induced by 1nmol/L NE, 10nmol/L ISO, 1 µmol/L forskolin,  10 µmol/L rolipram, 3 
10 µmol/L cilostamide or 10 µmol/L BAY 60-7550 measured in NRVMs using real-time FRET 4 
imaging (ne4 cells). (B) Cell surface area of NRVMs treated for 48 hours with NE (10 µmol/L), ISO 5 
(10 µmol/L), forskolin (1 µmol/L), rolipram (10 µmol/L), cilostamide (10 µmol/L), and BAY 60-7550 6 
(10 µmol/L) or untreated control.  ne32 cells. (C) [3H] leucine incorporation (n e 16 independent 7 
experiments) and (D) NFAT-GFP nuclear translocation measurements (minimum of 3 independent 8 
experiments) calculated for untreated NRVMs, or NRVMs treated as indicated. (E) FRET 9 
measurements of cAMP levels in NRVMs upon stimulation with NE (1 nmol/L), and NE in 10 
combination with 10 µmol/L rolipram, 10 µmol/L cilostamide or 10 µmol/L BAY 60-7550. (F) Cell 11 
surface area (ne44 cells), (G) [3H] leucine incorporation (n e 27 independent experiments), (H) 12 
normalised protein content and (I) NFAT-GFP nuclear translocation measured in NRVMs untreated 13 
or treated for 48 hours as indicated. (J) Cell surface area (minimum of n=128 cells per condition) 14 
and (K) NFAT-GFP nuclear translocation (minimum of 5 independent experiments) for control, NE 15 
(10 µmol/L)-treated NRVMs and NRVMs treated with NE (10 µmol/L) and transfected either with 16 
siPDE2 or with the control oligo siGLO Red. (L) Cell surface area of NRVMs treated for 48 hours 17 
CIRCRES/2014/305892D/R1 11 
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as indicated; PE (1 µmol/L), BAY 60-7550 (10 µmol/L); ne135 cells.  All data represent mean ± 1 
s.e.m. One-way ANOVA and Tukey’s multiple comparison tests were performed. Pixel size = 2 
0.1075 µm. * pd0.05; ** pd0.01; *** pd0.005; ns = not significant.  3 
  4 
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 1 
Figure 2. PDE2 inhibition attenuates cardiac hypertrophy in vivo. 2 
(A) Representative mid ventricular MRI short axis images of left ventricle in end diastole treated for 3 
3 weeks as indicated. (B) Left ventricular weight calculated from MRI recordings divided by body 4 
weight as indicated. (C) Representative heart sections obtained from mouse hearts extracted 3 5 
weeks after sham or TAC operation in the absence or presence of treatment, as indicated. (D) Left 6 
ventricular weight, body weight ratio (LVW/BW) plotted against the systolic pressure gradient 7 
calculated as a difference between right and left carotid systolic blood pressure (” P) at 3 weeks 8 
after sham operation, TAC, TAC+vehicle or TAC+BAY 60-7550 (3 mg/kg). (E) Summary and 9 
comparison of mean LVW/BW ratio values calculated for all sham-operated, TAC, TAC+vehicle or 10 
TAC+BAY 60-7550 treated mice. (F) Mean LVW/BW ratio values calculated for TAC, TAC+vehicle 11 
or TAC+BAY 60-7550 treated mice presenting with a ” P within the 30-40mmHg range. (G) 12 
Representative images of picrosirius red staining of heart sections generated after 3 weeks of TAC 13 
and treatment with vehicle or BAY 60-7550. In each panel, the contour of a representative cell is 14 
highlighted with a black line. Scale bar = 40 µm (H) Summary of myocyte cross-sectional area from 15 
sham, TAC, TAC+vehicle and TAC+BAY 60-7550 treated hearts (mean ± s.e.m of at least n=213 16 
CIRCRES/2014/305892D/R1 13 
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cells per condition). One-way ANOVA and Tukey’s multiple comparison tests were performed in all 1 
experiments. *pd0.05; **pd0.01; ***pd0.005. 2 
  3 
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Figure 3. PDE2 overexpression induces cardiac myocyte hypertrophic growth in vitro and in 2 
vivo. 3 
(A) Overlay of differential interference contrast (DIC) and fluorescence images showing in the 4 
same field one NRVM overexpressing PDE2Awt-mRFP and one untransfected control 5 
cardiomyocyte. Cell contour is highlighted in white (Scale bar: 10 µm). (B) Cell surface area (3 6 
independent experiments, ne49) calculated for untransfected NRVMs or NRVMs overexpressing 7 
PDE2Awt-mRFP (Pixel size = 0.1075 µm). (C-D) Percentage of cells showing nuclear translocation 8 
of NFAT-GFP measured for untransfected control NRVMs, NRVMs overexpressing PDE2Awt-9 
mRFP or PDE2A2dn-mRFP (4 independent experiments, total cell number e47).(E) 10 
Representative images of a untransduced (left panel) and transduced ARVMs expressing 11 
AdV5/PDE2Awt-mCherry (middle panel) or the catalytically inactive ADV5/PDE2Adn-mCherry 12 
(right panel). (F) Summary of cell surface area of ARVMs transduced with AdV5/PDE2wt-mCherry 13 
and untransduced myocytes isolated from the same heart. (G) Cell surface area of ARVMs 14 
obtained from hearts injected with AdV5/PDE2Adn-mCherry and expressing or not expressing the 15 
catalytically inactive recombinant enzyme. Consistent results were obtained from hearts from 3 16 
different animals injected with AdV5/PDE2Awt-mcherry and 3 animals injected with 17 
AdV5/PDE2Adn-mcherry; number of cells for each condition e100. Pixel size = 0.1613 µm. All data 18 
represent mean ± s.e.m. For all experiments t-test statistical analysis was performed. * p d 0.05, 19 
*** pd0.005. 20 
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Figure 4. The anti-hypertrophic effect of PDE2 inhibition is PKA-dependent. 2 
(A) Cell surface area (3 independent experiments, ne72) and (B) NFAT-GFP nuclear translocation 3 
(3 independent experiments, n e50) measurements for untreated control, NRVMs treated for 48 4 
hours with NE (10 µmol/L) or DT-2 (10 µmol/L), or treated with DT-2 in combination with NE, NE 5 
and BAY 60-7550 (10 µmol/L), or NE and sildenafil (10 nmol/L), as indicated. ((C) Cell surface 6 
area (3 independent experiments, ne54) and (D) percentage of NFAT-GFP nuclear translocation (4 7 
independent experiments, n e76) calculated for untreated control, NRVMs treated for 48 hours with 8 
NE (10 µmol/L) or myrPKI alone (10 µmol/L), or in combination with NE, or NE and BAY 60-7550 9 
(10 µmol/L), NE and sildenafil (10 nmol/L)as indicated. (E-F) NFAT-GFP nuclear translocation 10 
measurements (3 independent experiments) for untreated control, NE (10 µmol/L)-treated NRVMs 11 
or NRVMs treated with NE (10 µmol/L) and transfected either with siPDE2 or with the control oligo 12 
siGLO Red in the presence or absence of DT-2 (10 µmol/L) or of  myrPKI (10 µmol/L). (G) [3H] 13 
leucine incorporation assay performed in NRVMs treated with NE in combination with BAY 60-14 
7550 (10 µmol/L) and the PKA inhibitors H89 or cAMPS-Rp (n e 4 independent experiments). (H) 15 
NFAT-GFP nuclear translocation measurements (2 independent experiments) for untreated 16 
control, NRVMs transfected with Ht31 and treated with NE and BAY 60-7550. All data represent 17 
mean ± s.e.m. One-way ANOVA and Tukey’s multiple comparison tests were utilised. Pixel size = 18 
0.1075 µm. * p d 0.05, ** p d 0.01, *** pd0.005. 19 
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Figure 5. PDE2 modulates a local pool of cAMP with anti-hypertrophic effects. 2 
NRVM were transfected with catalytically inactive PDE4D3 (panels A, B), catalytically inactive 3 
PDE3A2 (panels C, D) or catalytically inactice PDE2A (panels E, F) and cells surface area was 4 
measured in the absence or presence of 10 µmol/L NE for 48 hrs. In each panel, the cell surface 5 
area is shown as mean ± s.e.m on the left and on the right an overlay of DIC and fluorescence 6 
images showing one NRVM overexpressing the catalytically inactive PDE and in the same field a 7 
non-transfected control cardiomyocyte is presented. For all conditions ne25 cells from three 8 
independent experiments. Pixel size = 0.1075 µm. Scale bar: 10 µm. For all experiments t-test 9 
statistical analysis was performed. *** pd 0.005; ns= not significant. 10 
  11 
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Figure 6. PKAII mediates the anti-hypertrophic effects of BAY 60-7550. 2 
Quantification of cAMP changes induced by BAY 60-7550 (10µmol/L), NE (10nmol/L), NE plus 3 
BAY 60-7550 (A) or by cilostamide (10µmol/L), NE (10nmol/L), or NE plus cilostamide (B), or by 4 
rolipram (10µmol/L), NE (10nmol/L), or NE plus rolipram (C) in NRVMs expressing either RI-epac 5 
or RII-epac. ne4. (D)  Quantification of PKA isoform-selective activation induced by isoproterenol 6 
(10nmol/L) and BAY 60-7550 measured in NRVMs expressing the FRET sensors RI_AKAR3 or 7 
RII_AKAR316. ne3. (E) Percentage of cells showing nuclear translocation of NFAT-GFP (F) and 8 
cell size measured for NE-treated or NE+BAY 60-7550 treated NRVMs untrasfected or transfected 9 
with either SuperAKAP-IS or RI-AD. ne4. (G) Cell surface area measurements of NRVMs treated 10 
for 48 hours as indicated. Cell size measured untrasfected NRVMs or NRVMs transfected with 11 
either SuperAKAP-IS or RI-AD and treated with cilostamide (H) or rolipram (I) as indicated; ne34. 12 
All data represent mean ± s.e.m. For experiments in A-D a t-test statistical analysis was performed. 13 
In  E-I, one-way ANOVA and Tukey•s multiple comparison tests were utilised.  *** pd 0.005; ** p 14 
d0.01; * p d 0.05; ns= not significant. 15 
  16 
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Figure 7. The anti-hypertrophic effect of PDE2 inhibition requires PKA-mediated 2 
phosphorylation of NFAT. 3 
(A) Representative GFP-pull down experiment from lysate of NRVMs expressing NFAT-GFP, PKI-4 
mcherry or mcherry. Cells were treated with NE (10 µmol/L) and BAY 60-7550 (10 µmol/L) as 5 
indicated. Blots were probed with anti Phospho-PKA substrate, anti GFP and anti GAPDH 6 
antibodies. n= 3. (B) Representative GFP-pull down experiment from lysate of NRVMs expressing 7 
NFAT-GFP and treated with NE (10 µmol/L), BAY 60-7550 (10 µmol/L) and Rolipram (10 µmol/L)  8 
as indicated. Blots were probed with anti Phospho-PKA substrate, anti GFP and anti GAPDH 9 
antibodies. n= 3.(C) Representative immunoprecipitation of endogenous NFAT performed on 10 
lysates from NRVMs treated with NE, BAY 60-7550 and rolipram as indicated. Blots were probed 11 
with anti Phospho-PKA substrate, anti NFAT and anti GAPDH antibodies. n = 3 (D) Nuclear 12 
translocation of NFAT-GFP wild type or NFAT-GFP triple mutant (S245A/S269A/S294A) calculated 13 
for untreated NRVMs, NRVMs treated for 48 hours with NE (10 µmol/L), NE and BAY 60-7550 (10 14 
µmol/L), NE and sildenafil (10 nmol/L), or NE and rolipram (10 µmol/L); n=3 independent 15 
experiments. (E) Representative immunoprecipitation of endogenous NFAT performed on mouse 16 
left ventricles whole cell lysates from sham, TAC+vehicle or TAC+BAY 60-7550 mice as indicated. 17 
Blots were probed with anti Phospho-PKA substrate, anti NFAT and anti GAPDH antibodies. 18 
Represaentative of 4 independent experiments (F) BNP (left) and RCAN1.4 (right) mRNA levels 19 
measured in LV samples from sham, TAC+vehicle or TAC+BAY 60-7550 mice as indicated (n=3-20 
7). (G) Quantification of NFAT luciferase activity in LV homogenates from TAC mice after two 21 
weeks treatment with BAY 60-7550, normalized to sham values. Four repeats per sample was 22 
performed. All data represent mean ± s.e.m. In D t-test was utilised, one-way ANOVA and Tukey’s 23 
multiple comparison tests were performed in F and G. Pixel size= 0.1075 µm. * p d 0.05; ** p 24 
d0.01; ns= not significant. 25 
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